NR509 Chamberlain Final Exam Review 2026/2027 | Advanced Physical Assessment Questions & Verified Answers with Detailed Rationales | Grade A Prep | APRN & FNP Clinical Assessment | Downloadable PDF

INSTANT PDF DOWNLOAD — This is the comprehensive Final Exam Review for NR509 - Advanced Physical Assessment (2026/2027) at Chamberlain University, featuring advanced physical assessment questions with verified answers and detailed rationales. Designed for Advanced Practice Registered Nurse (APRN) and Family Nurse Practitioner (FNP) students, this resource consolidates the essential advanced assessment concepts required to master the NR509 Final Exam and excel in clinical practice. The guide is meticulously aligned with Chamberlain University curriculum, APRN consensus model competencies, and current evidence-based advanced health assessment standards. This verified resource provides comprehensive coverage of key NR509 Advanced Physical Assessment Final Exam topics, including: Comprehensive Health History (chief complaint (patient's own words, duration, severity), history of present illness (HPI)—OLDCARTS (Onset (sudden vs gradual), Location (specific, radiating), Duration (constant vs intermittent), Characteristics (sharp, dull, burning, stabbing, throbbing, pressure, tearing, squeezing), Aggravating factors, Relieving factors, Timing (relationship to activity, meals, sleep, menstrual cycle), Severity (0-10 scale, functional impact), Associated symptoms, pertinent positives and negatives), past medical history (childhood illnesses, adult chronic diseases (hypertension, diabetes, CAD, COPD, asthma, CHF, CKD, liver disease, thyroid disease, autoimmune disorders, cancer, psychiatric disorders, substance use disorders), surgeries (dates, indications, complications), hospitalizations, injuries, transfusions, immunizations (influenza, Tdap/Td, MMR, varicella, hepatitis B, HPV, pneumococcal (PCV13, PPSV23), meningococcal, zoster, COVID-19, RSV), pregnancy history (gravida/para (GTPAL)), menstrual history (menarche, LMP, cycle regularity, duration, flow, dysmenorrhea, intermenstrual bleeding, postmenopausal bleeding, menopause date, symptoms), sexual history (sexually active, partners, condom use, contraception, STI history, sexual function (desire, arousal, orgasm, pain), orientation, gender identity, IPV screening), family history (first-degree relatives (parents, siblings, children), second-degree relatives (grandparents, aunts, uncles), age and health status, age and cause of death, specific conditions (hypertension, CAD, early MI (55 male, 65 female), stroke, diabetes, hyperlipidemia, cancer (type, age onset—breast, ovarian, colon, prostate, pancreatic, melanoma, lung), thyroid disease, autoimmune disorders (lupus, RA, MS), kidney disease, dementia/Alzheimer's, seizure disorder, psychiatric disorders, substance use disorders, genetic disorders (cystic fibrosis, Huntington's, sickle cell, hemophilia, Marfan, Ehlers-Danlos, polycystic kidney disease), sudden cardiac death 50 years, clotting disorders (DVT/PE, Factor V Leiden, prothrombin mutation), consanguinity), social history (occupation (exposures—chemicals, toxins, radiation, asbestos, silica, coal dust, pesticides, heavy metals, solvents, noise, vibration, repetitive motion, lifting, prolonged standing/sitting, shift work, stress), living situation (housing type, homeless, unsafe housing, environmental exposures (mold, lead, radon, asbestos, secondhand smoke, poor air quality, contaminated water), household members, marital status, support system, education level, financial status, insurance, food security, transportation, military history (branch, years, deployments, combat exposure, exposures (Agent Orange, burn pits, depleted uranium, Gulf War illness, blast injury, TBI), VA benefits), spiritual/religious beliefs (importance in healthcare, practices, dietary restrictions, blood transfusion beliefs, organ donation, advance care planning), advance directives (living will, durable power of attorney for healthcare, DNR/POLST, organ donor status), functional assessment (ADLs (bathing, dressing, toileting, transferring, continence, feeding), IADLs (meal preparation, shopping, housekeeping, laundry, managing finances, managing medications, using telephone/technology, transportation), physical function (gait, balance, mobility, falls history, assistive devices, ability to climb stairs, exercise (type, frequency, duration, intensity), limitations due to pain, weakness, shortness of breath, fatigue, dizziness), driving status, safety (falls risk, home hazards, elder abuse, domestic violence, IPV screening), substance use (alcohol—CAGE, AUDIT-C, quantity/frequency, heavy drinking, binge drinking, withdrawal, previous treatment, rehab, AA/NA, sobriety date; tobacco—cigarettes (pack-years), e-cigarettes/vaping, smokeless tobacco, cigars, pipe, age started, quit attempts, cessation methods, motivation to quit, nicotine withdrawal symptoms, secondhand smoke exposure; illicit drugs (marijuana/cannabis (frequency, quantity, method, age started, medical marijuana card, CBD use, CUD screening), stimulants (cocaine, crack, methamphetamine, amphetamine, MDMA)—frequency, route, last use, withdrawal, complications; opioids (heroin, prescription opioids)—frequency, route, last use, opioid use disorder screening (CAGE-AID, OWLS), withdrawal symptoms, treatment (methadone, buprenorphine, naltrexone), naloxone; benzodiazepines (prescribed, illicit), dependence, tolerance, withdrawal (seizures, delirium tremens-like, life-threatening, taper, do not abruptly discontinue); sedative-hypnotics (zolpidem, zaleplon, eszopiclone, barbiturates, carisoprodol, meprobamate, GHB); hallucinogens (LSD, psilocybin, mescaline, DMT/ayahuasca, ketamine, PCP, MDMA, salvia, synthetic cannabinoids (K2, Spice), synthetic cathinones (bath salts)); inhalants (volatile hydrocarbons, nitrous oxide, amyl nitrite, alkyl nitrites), side effects, withdrawal, caffeine (daily intake, withdrawal symptoms), medical cannabis (certifying condition, CBD:THC ratio, route, duration, adverse effects, interactions), nutrition (diet history (24-hour recall, food frequency, typical meals, snacks, portion sizes, dietary patterns (Mediterranean, DASH, vegetarian, vegan, keto, low-carb, paleo, intermittent fasting, gluten-free, dairy-free, low-FODMAP, low-residue), food allergies, preferences, aversions, cultural/religious dietary restrictions, special diets (dysphagia, bariatric surgery, diabetes, hypertension, heart failure, CKD, liver disease), malnutrition risk (unintentional weight loss (5% in 1 month or 10% in 6 months), decreased oral intake, muscle wasting, low albumin/prealbumin, chewing/swallowing problems, nausea/vomiting, diarrhea, constipation, early satiety, anorexia, food insecurity), physical activity (type, frequency, duration, intensity, sedentary time, barriers, readiness to change, exercise prescription (150 min moderate or 75 min vigorous aerobic per week + 2 days strength training + 2-3 days flexibility + balance exercises for older adults), precautions), sleep (typical bedtime/wake time, total sleep duration, sleep latency, nighttime awakenings (number, duration, reason), early morning awakening, daytime naps (frequency, duration, effect on nighttime sleep), sleep quality (refreshed vs unrefreshed), snoring (loudness, frequency, positional, witnessed apnea, gasping, choking), Epworth Sleepiness Scale (10 excessive daytime sleepiness), STOP-BANG questionnaire for OSA, restless legs syndrome (urge to move legs, worse at rest/bedtime, relieved by movement, worse in evening/night, causes: iron deficiency (ferritin, transferrin saturation), pregnancy, renal failure, peripheral neuropathy, medications (antidepressants (SSRIs, SNRIs, TCAs, mirtazapine), antipsychotics (olanzapine, risperidone, quetiapine), antihistamines (diphenhydramine, hydroxyzine), dopamine antagonists (metoclopramide, prochlorperazine), lithium, caffeine, nicotine, alcohol withdrawal), treatment (iron supplementation if ferritin 75 mcg/L, non-pharmacologic (avoid triggers, massage, heat/cold, moderate exercise, good sleep hygiene), pharmacologic (gabapentin enacarbil (Horizant), pregabalin (Lyrica) first-line; dopamine agonists (pramipexole, ropinirole)—risk of augmentation; benzodiazepines (clonazepam) for sleep disturbance; opioids for refractory RLS), circadian rhythm disorders (delayed sleep phase, advanced sleep phase, shift work disorder, irregular sleep-wake rhythm, jet lag disorder), insomnia disorder (difficulty falling asleep, staying asleep, or early morning awakening with daytime consequences (fatigue, mood disturbance, cognitive impairment, impaired function), duration (3 months acute, ≥3 months chronic), frequency (≥3 nights per week), DSM-5-TR criteria, sleep hygiene, CBT-I first-line (stimulus control, sleep restriction, cognitive restructuring, relaxation training, sleep hygiene education, paradoxical intention), pharmacologic for insomnia (short-term only, avoid in chronic insomnia unless CBT-I not available/effective—benzodiazepine receptor agonists (zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), triazolam (Halcion), temazepam (Restoril), flurazepam (Dalmane), quazepam (Doral), estazolam (Prosom)), doxepin (low dose 3-6 mg for sleep maintenance), ramelteon (melatonin receptor agonist—sleep onset), suvorexant, lemborexant, daridorexant (orexin receptor antagonists—sleep onset/maintenance), melatonin (0.5-5 mg, over-the-counter, not FDA-regulated, short-term use), trazodone (25-100 mg off-label, risk priapism), mirtazapine (7.5-15 mg off-label, weight gain, sedation), amitriptyline (10-50 mg off-label, anticholinergic, cardiac risk), gabapentin (300-1200 mg off-label for insomnia with RLS or pain), quetiapine (12.5-100 mg off-label for insomnia, weight gain, metabolic syndrome, tardive dyskinesia, not first-line), diphenhydramine (Benadryl, Unisom) over-the-counter, anticholinergic, cognitive impairment, fall risk in elderly, tolerance develops quickly, avoid chronic use), REM sleep behavior disorder (loss of atonia during REM, acting out dreams (punching, kicking, shouting, jumping out of bed), associated with alpha-synucleinopathies (Parkinson's, dementia with Lewy bodies, multiple system atrophy), can precede Parkinson's by decades, clonazepam